Evidence map›Paper›PMID 41219403›Full record

ArticleNPJ precision oncology2025

Role of repulsive guidance signaling and GPR180 in pediatric low-grade glioma infiltration.

Geena Jung, Zizhuo Liang, Payal Jain, Hannah M Deutsch, Feng Li, Komal S Rathi, Zhichuan Sun, Xin Chen, Joshua Straka, Anahita Fathi Kazerooni and 9 more

Abstract read
In one paragraph

Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Geena Jung *Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Zizhuo Liang *Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Payal Jain *Center for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Hannah M Deutsch *Raymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Feng LiRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Komal S RathiCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Zhichuan SunDepartment of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
Xin ChenProgram in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada.
Joshua StrakaCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Anahita Fathi KazerooniCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Yuqi SunRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA.
Mateusz P KoptyraCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Stephanie Sanchez-MaldonadoCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Ariana FamiliarCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Angela J WaandersDivision of Hematology, Oncology, NeuroOncology, and Stem Cell Transplant, Ann & Robert H Lurie Children's Hospital of Chicago, Chicago, IL, USA.
Ali NabavizadehCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA.
Xi HuangProgram in Developmental and Stem Cell Biology, The Hospital for Sick Children, Toronto, ON, Canada.
Adam C ResnickCenter for Data-Driven Discovery in Biomedicine (D3b), Children's Hospital of Philadelphia, 3501 Civic Center Boulevard, Philadelphia, PA, USA. resnick@chop.edu.
Yuanquan SongRaymond G. Perelman Center for Cellular and Molecular Therapeutics, Children's Hospital of Philadelphia, Philadelphia, PA, USA. songy2@chop.edu.

Funding

U2C Kids First Admin Supplement - data transferU2CHL138346 · NHLBI · CHILDREN'S HOSP OF PHILADELPHIA · PI HEATH, ALLISON · 2017 to 2022
$21.5M
Targeting Atr to promote regeneration and functional recovery after neural injuryR01NS107392 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI SONG, YUANQUAN · 2018 to 2022
$1.9M
Pediatric low-grade gliomas: biology and molecular targeting.R01NS085336 · NINDS · CHILDREN'S HOSP OF PHILADELPHIA · PI RESNICK, ADAM CAIN · 2014 to 2018
$1.8M
NHLBI NIH HHS U2C HL138346NIH HHS 1R01NS107392NIH HHS R01NS085336NINDS NIH HHS R01 NS085336NINDS NIH HHS R01 NS107392
6 · The paper itself

Abstract

Pediatric low-grade gliomas (pLGGs) are the most common brain tumors in children with varying degrees of infiltration. Despite having a positive prognosis, if the standard treatment, gross total resection, is impossible due to tumor location or diffuseness, outcomes worsen. Development of targeted therapeutics for diverse subtypes of pLGGs is limited by a lack of genetic models. We generated five fly pLGG models using patient-derived fusion genes to investigate molecular subtype-specific pathology, and found glial overexpression of QKI::RAF1, associated with pilocytic astrocytomas and glioneuronal tumors, induced aberrant glial migration and infiltration. Both repulsive guidance signaling and GPR180/CG9304 mediated glial infiltration, which was suppressed by glial overexpression of Robo2 or PlexA/B, or knockdown of GPR180/CG9304. ROBO2 and GPR180/CG9304 were down and upregulated, respectively, in flies and patients with RAF fusions. Our study provides mechanistic insights into pLGG tumorigenesis and suggests targeting repulsive guidance signaling and GPR180/CG9304 as potential therapeutics for pLGG subtypes.

Identifiers

PMID41219403
PMCPMC12606276

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.